Enhancing activity of CAR T cells by co-introducing a bispecific antibody

1. An ex vivo or in vitro method of generating a modified T cell, comprising introducing into a T cell a composition comprising

(a) a first RNA molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain, a transmembrane domain, and a CD3 zeta signaling domain; and

(b) a second RNA molecule encoding a bispecific antibody, wherein the bispecific antibody comprises a first antigen recognition domain that recognizes the same antigen as the antigen binding domain of the CAR, and a second antigen recognition domain that recognizes CD3 wherein the bispecific antibody encoded by the second RNA molecule is secreted by the cell.

2. The method of claim 1 , wherein the CAR further comprises a costimulatory signaling region.

3. An ex vivo or in vitro method of enhancing an anti-tumor activity of a T cell, comprising introducing into a T cell a composition comprising

(a) a first RNA molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain, a transmembrane domain, and a CD3 zeta signaling domain; and

(b) a second RNA molecule encoding a bispecific antibody, wherein the bispecific antibody comprises a first antigen recognition domain that recognizes the same antigen as the antigen binding domain of the CAR, and a second antigen recognition domain that recognizes CD3,

wherein the bispecific antibody encoded by the second RNA is secreted by the cell, and wherein the secreted bispecific antibody further stimulates the modified T cell and non-modified bystander T cells to specifically recognize tumor cells.

4. The ex vivo or in vitro method of claim 3 , wherein the antigen binding domain of the CAR binds CD19, CD20, CD22, ROR1, mesothelin, CD33/IL3Ra, c-Met, PSMA, Glycolipid F77, EGFRvIII, or GD-2.

5. The ex vivo or in vitro method of claim 3 , wherein the bispecific antibody is encoded by a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.

6. The ex vivo or in vitro method of claim 3 , wherein the CAR comprises a polypeptide encoded by the nucleic acid sequence selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22.

7. A T cell genetically modified to express a CAR and a bispecific antibody, wherein:

(a) the CAR comprises an antigen binding domain, a transmembrane domain, and a CD3 zeta signaling domain; and

(b) the bispecific antibody comprises a first antigen recognition domain that recognizes the same antigen as the antigen binding domain of the CAR, and a second antigen recognition domain that recognizes CD3,

(c) the bispecific antibody is secreted by the cell; and

(d) the secreted bispecific antibody further stimulates the modified T cell and non-modified bystander T cells to specifically recognize tumor cells.

8. The T cell of claim 7 , wherein the bispecific antibody comprises:

(a) a human antibody, or an antigen-binding fragment thereof, or

(b) a humanized antibody, or an antigen-binding fragment thereof.

9. The T cell of claim 7 , wherein the CAR further comprises a costimulatory signaling region.

10. A method of treating cancer in a human, comprising administering to the human the T cell of claim 7 .

11. An ex vivo or in vitro method of enhancing an anti-tumor activity of a T cell, comprising introducing into a T cell a composition comprising

(a) a first lentiviral vector encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain, a transmembrane domain, and a CD3 zeta signaling domain; and

(b) a second lentiviral vector encoding a bispecific antibody, wherein the bispecific antibody comprises a first antigen recognition domain that recognizes the same antigen as the antigen binding domain of the CAR, and a second antigen recognition domain that recognizes CD3,

wherein the bispecific antibody encoded by the second lentiviral vector is secreted by the cell, and wherein the secreted bispecific antibody further stimulates the modified T cell and non-modified bystander T cells to specifically recognize tumor cells.

12. The method of claim 11 , wherein the CAR further comprises a costimulatory signaling region.

13. The ex vivo or in vitro method of claim 11 , wherein the antigen binding domain of the CAR binds CD19, CD20, CD22, ROR1, mesothelin, CD33/IL3Ra, c-Met, PSMA, Glycolipid F77, EGFRvIII, or GD-2.

14. The ex vivo or in vitro method of claim 11 , wherein the bispecific antibody is encoded by a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.

15. The ex vivo or in vitro method of claim 11 , wherein the CAR comprises a polypeptide encoded by the nucleic acid sequence selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22.

16. An ex vivo or in vitro method of generating a modified T cell, comprising introducing into a T cell a composition comprising

(a) a first lentiviral vector encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain, a transmembrane domain, and a CD3 zeta signaling domain; and

(b) a second lentiviral vector encoding a bispecific antibody, wherein the bispecific antibody comprises a first antigen recognition domain that recognizes the same antigen as the antigen binding domain of the CAR, and a second antigen recognition domain that recognizes CD3 wherein the bispecific antibody encoded by the second lentiviral vector is secreted by the cell.